摘要
目的分析重组人干扰素α1b治疗小儿急性毛细支气管炎的效果。方法选取2017年1月—2017年12月笔者所在医院收治的178例小儿急性毛细支气管炎患者,将其随机分为研究组和对照组,每组各89例;研究组在基础治疗以外加用重组人干扰素α1b治疗,对照组利用基础治疗方法,比较两组治疗效果。结果两组三凹征消失时间、住院时间有统计学意义(P<0.05),研究组不良反应发生率3.37%,对照组不良反应发生率4.49%,差异不明显(P>0.05),两组咳嗽消失、喘息消失、啰音消失时间有统计学意义(P<0.05)。结论小儿急性毛细支气管炎发病后症状明显,直接影响患者生活与身体发育,利用基础治疗预后效果相对较差,加用重组人干扰素α1b治疗效果显著,安全性强,值得临床应用。
Objective To analyze the effect of recombinant human interferon α1b in the treatment of acute bronchiolitis in children. Methods From January 2017 to December 2017 , 178 children with acute bronchiolitis were randomly divided into study group and control group , 89 cases in each group who were treated with recombinant human interferon α1b in addition to basic treatment. Control group was only treated with basic treatment. The therapeutic effects of the two groups were compared. Results There were significant differences in the disappearance time of 3-凹 signs and hospitalization time between the two groups ( P<0.05 ). The incidence of adverse reaction was 3.37% in study group and 4.49% in control group , without significant difference between the two groups ( P>0.05 ). Conclusion Children with acute bronchiolitis after the onset of symptoms directly impact on the life and physical development of patients;the prognosis of basic treatment is relatively poor , but combined with recombinant human interferon α1b the treatment effect is significant , safe , worthy of clinical application.
作者
陆凤霞
LU Feng-xia(The Children's Hospital Affiliated to Zhengzhou University/Henan Provincial Children's Hospital and Zhengzhou Children's Hospital , the Second Infected Patch of the Department of Respiration , Zhengzhou , Henan 450000 , China)
出处
《实用医药杂志》
2019年第4期314-315,318,共3页
Practical Journal of Medicine & Pharmacy
